Enlicitide Decanoate (MK-0616)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Enlicitide Decanoate (MK-0616), covering 2024-10-03 to 2026-02-24. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH) [Phase 3]